Mirxes Holding (HKG:2629) raised HK$880.5 million in net proceeds from its initial public offering in Hong Kong.
The Singapore-headquartered micro ribonucleic acid technology company issued 46.6 million shares at HK$23.30 each, according to a Thursday filing with the Hong Kong Exchange.
The deal's Hong Kong public offering portion was 25.5 times subscribed, prompting the company to issue 5.87 million shares, up from the 4.66 million shares initially allotted.
The international offering portion was 0.98 times subscribed, and the firm issued 40.7 million shares, lower than the initial allocation of 41.9 million.
The cornerstone investors subscribed to a total of 19.2 million IPO shares.
Mirxes starts trading on the Hong Kong bourse today, May 23.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.